Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Autoimmune hepatitis--an update.

K H Meyer zum Büschenfelde1, T Poralla

  • 1I. Medizinische Klinik und Poliklinik, Johannes Gutenberg-Universität, Mainz, Germany.

Behring Institute Mitteilungen
|April 1, 1992
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Autoimmune hepatitis.

The New England journal of medicine·1995
Same author

A new hepatocyte stimulating factor: cardiotrophin-1 (CT-1).

FEBS letters·1995
Same author

Klebsiella pneumoniae-reactive T cells in blood and synovial fluid of patients with ankylosing spondylitis. Comparison with HLA-B27+ healthy control subjects in a limiting dilution study and determination of the specificity of synovial fluid T cell clones.

Arthritis and rheumatism·1995
Same author

A p16INK4a-insensitive CDK4 mutant targeted by cytolytic T lymphocytes in a human melanoma.

Science (New York, N.Y.)·1995
Same author

[Therapy refractory atypical polyarthritis and cryoglobulinemia in a patient with colon carcinoma and palliative intestinal bypass. Differential diagnosis: carcinoma-polyarthritis or bypass arthritis].

Zeitschrift fur Gastroenterologie·1995
Same author

Autoimmune hepatitis following hepatitis A virus infection.

Journal of hepatology·1995

Autoimmune chronic active hepatitis (ai-CAH) is a progressive liver disease diagnosed using marker autoantibodies. Early diagnosis and immunosuppression improve prognosis, with liver transplantation as a viable option for treatment-resistant cases.

Area of Science:

  • Hepatology
  • Immunology
  • Internal Medicine

Background:

  • Autoimmune chronic active hepatitis (ai-CAH) is a progressive inflammatory liver disease with an unknown cause and poor prognosis if untreated.
  • Early diagnosis is crucial for effective management and improved patient outcomes.
  • Advances in identifying marker autoantibodies have aided in diagnosing disease subgroups and understanding pathogenesis.

Purpose of the Study:

  • To review the diagnostic advancements in autoimmune chronic active hepatitis (ai-CAH).
  • To explore the role of autoantibodies in ai-CAH pathogenesis and classification.
  • To discuss current and future therapeutic strategies for ai-CAH.

Main Methods:

  • Review of diagnostic marker autoantibodies for ai-CAH subgroups.

Related Experiment Videos

  • Analysis of autoantibody targets, including intracellular structures and liver cell surface components like the asialoglycoprotein receptor (ASGPR).
  • Evaluation of therapeutic outcomes with immunosuppression and liver transplantation.

    • Main Results:

    • Marker autoantibodies facilitate the diagnosis and subgrouping of ai-CAH.
    • Autoantibodies targeting intracellular structures and liver cell surface components (e.g., ASGPR) provide insights into disease mechanisms.
    • Combined immunosuppression improves symptoms and survival, while liver transplantation offers a promising alternative for non-responders.

    Conclusions:

    • Early diagnosis of ai-CAH using autoantibody panels is essential.
    • Understanding autoantibody targets deepens insights into ai-CAH pathogenesis.
    • Effective management involves immunosuppression, with liver transplantation as a key therapeutic option for advanced disease.